Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18(1):22.

Petridis C, Brook MN, Shah V et al.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2015;108(2). pii: djv315.

Meeks HD, Song H, Michailidou K et al.

CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer. 2016;23(2):77-91.

Thompson DJ, O'Mara TA, Glubb DM et al.

Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet. 2016;135(1):137-54.

Lei J, Rudolph A, Moysich KB et al.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016;141(2):386-401.

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A et al.

Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Sci Rep. 2015;5:17369.

Cheng TH, Thompson D, Painter J et al.

Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1680-91.

Guo X, Long J, Zeng C et al.

Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. J Natl Cancer Inst 2015; 107:djv219.

Zhang B, Shu XO, Delahanty RJ et al.

Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015;7(1):67.

Van Veldhoven K, Polidoro S, Baglietto L et al.

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet. 2015;47(9):987-95.

Law MH, Bishop DT, Lee JE et al.


Subscribe to Publications